These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 2526152)

  • 1. Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma.
    Waibel-Treber S; Minne HW; Scharla SH; Bremen T; Ziegler R; Leyendecker G
    Hum Reprod; 1989 May; 4(4):384-8. PubMed ID: 2526152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium homeostasis, bone metabolism and safety aspects during long-term treatment with a GnRH agonist.
    Eckstein N; Foldes J; Feinstein Y; Vagman I; Eshel A; Steinberg R; Statter M; Limor R; Ayalon D
    Maturitas; 1992 Aug; 15(1):25-32. PubMed ID: 1388219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone mass reduction after estrogen deprivation by long-acting gonadotropin-releasing hormone agonists and its relation to pretreatment serum concentrations of 1,25-dihydroxyvitamin D3.
    Scharla SH; Minne HW; Waibel-Treber S; Schaible A; Lempert UG; Wüster C; Leyendecker G; Ziegler R
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1055-61. PubMed ID: 2138629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid reduction of uterine leiomyomas with monthly injections of D-Trp6-GnRH.
    van Leusden HA; Dogterom AA
    Gynecol Endocrinol; 1988 Mar; 2(1):45-51. PubMed ID: 2972173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of treatment with GnRH agonists on new markers of bone metabolism.
    Kukuvitis A; Bildiris J; Prapas Y; Tsamis D; Papadimas J; Dimitriadou A; Vlassis G
    Gynecol Obstet Invest; 1999; 47(3):194-6. PubMed ID: 10087416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum CA 125 concentrations in women with endometriosis or uterine fibroids treated with gonadotrophin-releasing hormone agonist analogues.
    van der Spuy ZM; Wood M; Fieggen G; Hendricks MS
    S Afr Med J; 1993 Jul; 83(7):510-3. PubMed ID: 8211493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oestrogen deficiency causes DNA damage in uterine leiomyoma cells: a possible mechanism for shrinkage of fibroids by GnRH agonists.
    Cheng YM; Chou CY; Huang SC; Lin HC
    BJOG; 2001 Jan; 108(1):95-102. PubMed ID: 11213012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri.
    Friedman AJ; Daly M; Juneau-Norcross M; Rein MS; Fine C; Gleason R; Leboff M
    J Clin Endocrinol Metab; 1993 Jun; 76(6):1439-45. PubMed ID: 8501148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl).
    Lindsay PC; Shaw RW; Bennink HJ; Kicovic P
    Fertil Steril; 1996 Feb; 65(2):342-8. PubMed ID: 8566259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GnRH agonists-antagonists--clinical applications.
    Shaw RW
    Eur J Obstet Gynecol Reprod Biol; 1988 Jun; 28(2):109-16. PubMed ID: 2969835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism.
    Palomba S; Orio F; Morelli M; Russo T; Pellicano M; Nappi C; Mastrantonio P; Lombardi G; Colao A; Zullo F
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4476-81. PubMed ID: 12364422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The GnRH agonists in the treatment of uterine leiomyomas.
    Bianchi S; Fedele L
    Acta Eur Fertil; 1989; 20(1):5-10. PubMed ID: 2675524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration.
    Taga M; Minaguchi H
    Acta Obstet Gynecol Scand; 1996 Feb; 75(2):162-5. PubMed ID: 8604604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [GnRH-analogs in the therapy of uterine myomatosis].
    Wieacker P; Geisthövel F; Adelberger V; Breckwoldt M
    Ther Umsch; 1990 Dec; 47(12):951-7. PubMed ID: 2151405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency.
    Finkelstein JS; Klibanski A; Schaefer EH; Hornstein MD; Schiff I; Neer RM
    N Engl J Med; 1994 Dec; 331(24):1618-23. PubMed ID: 7969342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical application of luteinizing hormone releasing hormone agonist and its impact on bone metabolism].
    Zhang M; He Y; Cao S
    Zhonghua Fu Chan Ke Za Zhi; 1995 Jul; 30(7):398-401. PubMed ID: 7587574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone.
    Palomba S; Morelli M; Di Carlo C; Noia R; Pellicano M; Zullo F
    Fertil Steril; 2002 Jul; 78(1):63-8. PubMed ID: 12095492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical markers as predictors of bone mineral density changes after GnRH agonist treatment.
    Borderie D; Cherruau B; Dougados M; Ekindjian OG; Roux C
    Calcif Tissue Int; 1998 Jan; 62(1):21-5. PubMed ID: 9405728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy.
    Marshall LA; Cain DF; Dmowski WP; Chesnut CH
    Obstet Gynecol; 1996 Mar; 87(3):350-4. PubMed ID: 8598953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium metabolism in premenopausal women treated by a Gn-RH agonist for uterine myoma.
    Ito M; Sakoda Y; Okamura H
    Endocrinol Jpn; 1990 Dec; 37(6):907-13. PubMed ID: 1966283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.